EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

By B. Combe, R. Landewé, C. Lukas, Horatio D Bolosiu, F. Breedveld, M. Dougados, P. Emery, G. Ferraccioli, J. Hazes, Lars Klareskog and 6 more. Annals of the Rheumatic Diseases, 2006

863 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/5dd1152a373af8a7a7d48da541f94a47311d7a5d

Citations in the corpus

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, positive): “more recent data suggest that this approach may not be more effective in patients with early RA than starting synthetic DMARDs first and adding a biological agent to the DMARD rapidly (in that study after 3 months) if active disease prevails.”
• Treating rheumatoid arthritis to target: recommendations of an international task force (2010, critical): “66–68 However, none of these comprised the important aspects of specifi cally defi ning the treatment target for RA and detailing the ways to achieve the therapeutic goal.”
• Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research (2008, background): “Rheumatism (EULAR) and the American College of Rheumatology (ACR).(1) 2 This drug inhibits the”
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010, neutral): “43 47 Thus, remission is the primary therapeutic aim, especially in early RA, though low disease activity may be an appropriate alternative, especially in patients with longstanding RA, as was also concluded by an expert committee recently engaged in defi ning a treatment target for RA.”